DrugPatentWatch Database Preview
Details for Patent: 9,187,405
Which drugs does patent 9,187,405 protect, and when does it expire?
This patent has twenty-six patent family members in twelve countries.
Summary for Patent: 9,187,405
Title: | S1P receptor modulators for treating relasping-remitting multiple sclerosis |
Abstract: | The present invention relates uses of an S1P receptor modulator such as 2-substituted 2-amino-propane-1,3-diol or 2-amino-propanol derivatives, e. g. a compound comprising a group of formula X ##STR00001## for the treatment or prevention of neo-angiogenesis associated with a demyelinating disease, e.g. multiple sclerosis. |
Inventor(s): | Hiestand; Peter C. (Austria, CH), Schnell; Christian (Hesingue, FR) |
Assignee: | Novartis AG (Basel, CH) |
Application Number: | 14/257,342 |
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 9,187,405
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Patent Submitted |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Novartis | GILENYA | fingolimod | CAPSULE;ORAL | 022527-001 | Sep 21, 2010 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | TREATMENT OF AUTOIMMUNE DISEASE | ➤ Try a Free Trial | ||||
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Patent Submitted |
Foreign Priority and PCT Information for Patent: 9,187,405
Foriegn Application Priority Data | ||
Foreign Country | Foreign Patent Number | Foreign Patent Date |
United Kingdom | 0612721.1 | Jun 27, 2006 |
Non-Orange Book US Patents Family Members for Patent 9,187,405
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
Patent No. | Title | Estimated Patent Expiration |
---|---|---|
8,741,963 | S1P receptor modulators for treating multiple sclerosis | ➤ Try a Free Trial |
Patent No. | Title | Estimated Patent Expiration |
International Patents Family Members for US Patent 9,187,405
Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Australia | 2007264031 | ➤ Try a Free Trial | |||
Australia | 2011201844 | ➤ Try a Free Trial | |||
Australia | 2013200356 | ➤ Try a Free Trial | |||
Australia | 2016266058 | ➤ Try a Free Trial | |||
Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |